Kyodo Pharmaceutical: Announcement on changing the sponsor representative for continuous supervision
Kyodo Pharmaceutical: 2024 Semi-Annual Financial Report
Kyodo Pharmaceutical: Summary table on the use of non-operating capital and other related capital transactions for the first half year of 2024
Hubei Goto Biopharm: Legal opinion from Beijing Zhonglun (Wuhan) Law Firm regarding the 2024 second extraordinary general meeting of shareholders of Hubei Jointown Pharmaceutical Co., Ltd.
Hubei Goto Biopharm: Announcement of resolution of the Second Extraordinary Shareholders' Meeting in 2024.
Hubei Goto Biopharm: Announcement regarding not downwardly revising the price of debt-for-equity swaps.
Hubei Goto Biopharm: Announcement on the conditions for downward revision of the expected conversion price of convertible bonds.
Hubei Goto Biopharm: Notice Regarding the Holding of the Second Extraordinary Shareholders' Meeting in 2024.
Hubei Goto Biopharm: Announcement regarding the wholly-owned subsidiary's plan to apply for a comprehensive credit limit from banks and the company providing guarantee for it.
Hubei Goto Biopharm: Announcement on the conversion of convertible corporate bonds to stocks in Q2 2024.
Hubei Goto Biopharm: Hubei Jointown Pharmaceutical Group Co., Ltd.'s Main and Convertible Bonds 2024 Tracking Rating Report.
Hubei Goto Biopharm: Legal Opinion of Beijing Zhonglun (Wuhan) Law Firm on the 2024 First Temporary Shareholders' Meeting of Hubei Jointown Pharmaceutical Co., Ltd.
Hubei Goto Biopharm: Announcement of the resolution of the first extraordinary Shareholders' Meeting in 2024.
Hubei Goto Biopharm: CSI Enterprise Bond Index issued convertible corporate bonds to unspecified entities in Hubei and entrusted management affairs report (2023).
Hubei Goto Biopharm: Announcement regarding the adjustment of the conversion price for convertible bonds into shares.
Hubei Goto Biopharm: Notice on holding the 2024 First Extraordinary General Meeting of Shareholders
Hubei Goto Biopharm: Announcement on the wholly-owned subsidiary's intention to apply for a comprehensive credit line from the bank and the company will provide a guarantee for it
Hubei Goto Biopharm: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Hubei Goto Biopharm: Legal Opinion of Beijing Zhonglun (Wuhan) Law Firm on the 2023 Annual General Meeting of Shareholders of Hubei Joint Pharmaceutical Co., Ltd.
Hubei Goto Biopharm: Announcement on the wholly-owned subsidiary obtaining a laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment (CNAS)
No Data
No Data